SAS PROC GLM with group effect [General Sta­tis­tics]

posted by Silva – Portugal, 2014-05-23 14:12 (3616 d 05:10 ago) – Posting: # 12992
Views: 14,018

Thanks for all the input.

From all the discussions about group effect within the forum, a thought came to me? Do we really need to test Group effect? If not tested, what happens is the increase of MS error and therefore CI's are expected to be widened, which increases Producer's risk! Does FDA or EMA really ask for group effect?

For Bioequivalence statistics (ANOVA and CI's calculation), is it Phoenix so acceptable as SAS for FDA? And for EMA?

Rgs
Silva


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,651 registered users;
44 visitors (0 registered, 44 guests [including 7 identified bots]).
Forum time: 19:23 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5